Reproductive Equity Now Statement on 25th Anniversary of Mifepristone
“In a post-Roe world, medication abortion has become a lifeline.”
Boston, MA (September 26, 2025) – Ahead of Sunday’s 25th anniversary of the U.S. Food and Drug Administration’s (FDA) approval of mifepristone, one of two medications used in medication abortion care, Taylor St. Germain, interim co-executive director for Reproductive Equity Now, released the following statement.
“Twenty-five years ago, the approval of mifepristone transformed abortion access in the United States. Safe, effective, and FDA-approved for decades, mifepristone has become an essential tool in ensuring people can make their own decisions about their pregnancies and futures. In fact, medication abortion now accounts for more than half of all abortions nationwide. In a post-Roe world, medication abortion has become a lifeline.
“Despite that, Donald Trump and his administration have doubled down on their dangerous, anti-abortion agenda by announcing plans for his Department of Health to investigate this critical medication. This is nothing more than another politically-motivated attempt to control our bodies and strip away our freedoms.
“Reproductive Equity Now has fought — and will continue to fight — back against these relentless attacks. We are defending access across State Houses, while also going on offense to expand availability, protect providers, and ensure patients can safely get the care they need. Mifepristone is safe. It is essential. And we will never stop fighting to protect access to it.”
###
